Millipore Corp

Millipore — Q3 2006 Earnings Presentation

15 slides from Millipore's earnings presentation, Nov 3, 2006

  1. Slide 1: Accelerating Growth and Innovation: Millipore Q3 2006 Earnings Release Presentation

    1 ACCELERATING GROWTH AND INNOVATION Millipore Q3 2006 Earnings Release Presentation November 1, 2006

  2. Slide 2: Forward-looking Statements / Reg. G

    Forward-looking Statements / Reg. G In order to take advantage of the safe harbor provisions of the private securities litigation reform act of 1995, you should understand that we will be making forward-looking statements in this conference. These statements involve a number of risks and uncertainti

  3. Slide 3: Q3 2006 Highlights

    Q3 2006 Highlights o Strong quarter of revenue growth: 10%* o Continued progress in increasing profitability - Non-GAAP operating margins increased from 17.5% to 19.6% - Non-GAAP net income increased 20% o Successful execution of global supply chain program - Five-year program is generating savings

  4. Slide 4: Healthy growth in both divisions

    4 o Bioscience Division - Strong performance in North America - Good product launch in lab water o Bioprocess Division - Filtration and chromatography drive growth - Customers making investments in capacity and actively making acquisitions 13% 6% Bioscience Bioprocess Q3 2006 Revenue Growth* Healthy

  5. Slide 5: 2006 Growth (Nine months) is creating well-balanced growth profile

    5 13% 9% Bioscience Bioprocess 2006 Growth* (Nine months) is creating well-balanced growth profile *without Serologicals, adjusted for currency rate changes

  6. Slide 6: Revenue Growth Drivers

    6 Revenue Growth Drivers o Presence in faster growing markets o Better sales & marketing execution o Expansion in emerging markets oNew products o Go to market initiatives 6% 6% 10% 9% 2003 2004 2005 2006* Changes made last year are enabling Millipore to consistently deliver higher revenue growth Or

  7. Slide 7: Millipore Strategic Business Units

    7 Millipore Strategic Business Units Bio-Products & Technologies SBU Filtration & Chromatography SBU Process Monitoring Tools SBU Advanced Manufacturing Solutions SBU Bioscience DivisionBioprocess Division Drug Discovery SBU Laboratory Water SBU Research Reagents SBU Sample Prep & Biotools SBU

  8. Slide 8: Q3 2006 GAAP results

    8 Actual Dollars (In millions, except per share data) Q3 2006 Q3 2005 % Change Sales $ 330.1 $239.6 38% Gross profit 160.9 122.7 31% % of sales 48.7% 51.2% SG&A 106.9 72.6 47% % of sales 32.3% 30.3% R&D 24.6 18.9 31% % of sales 7.5% 7.9% Operating income 29.4 31.2 ( 6%) % of sales 8.9% 13.0% Net inc

  9. Slide 9: Q3 2006 GAAP to Non-GAAP Reconciliation

    Q3 2006 GAAP to Non-GAAP Reconciliation Reconciliation of GAAP to Non-GAAP Financial Measures Three Months Ended September 30, 2006 (dollars in thousands, except EPS data) Gross Profit Operating Operating Pre-tax Diluted Gross Profit Margin Income Margin Income Net Income EPS GAAP results, three mon

  10. Slide 10: Q3 2006 Non-GAAP Results

    10 Actual Dollars (In millions, except per share data) Q3 2006 Q3 2005 % Growth Sales $ 330.1 $239.6 38% Gross profit 181.6 129.0 41% % of sales 55.0% 53.9% Operating income 64.7 42.0 54% % of sales 19.6% 17.5% Net income $ 37.1 $31.1 20% EPS $ 0.69 $ 0.59 16% Q3 2006 Non-GAAP Results* * Please refe

  11. Slide 11: Nine Month GAAP Results

    11 Actual Dollars (In millions, except per share data) 2006 2005 % Growth Sales $ 872.3 $ 734.7 19% Gross profit 447.0 387.6 15% % of sales 51.2% 52.8% SG&A 276.6 230.5 20% % of sales 31.7% 31.4% R&D 62.8 52.3 20% % of sales 7.2% 7.1% Operating income 107.6 104.8 3% % of sales 12.3% 14.3% Net income

  12. Slide 12: Nine Months GAAP to Non-GAAP Reconciliation

    Nine Months GAAP to Non-GAAP Reconciliation Reconciliation of GAAP to Non-GAAP Financial Measures Nine Months Ended September 30, 2006 (dollars in thousands, except EPS data) Gross Profit Operating Operating Pre-tax Diluted Gross Profit Margin Income Margin Income Net Income EPS GAAP results, nine m

  13. Slide 13: Nine Month Non-GAAP Results

    13 Actual Dollars (In millions, except per share data) 2006 2005 % Growth Sales $ 872.3 $ 734.7 19% Gross profit 479.3 396.5 21% % of sales 54.9% 54.0% Operating income 164.1 134.8 22% % of sales 18.8% 18.4% Net income $ 115.8 $ 100.6 15% EPS $ 2.14 $ 1.97 9% Nine Month Non-GAAP results* * Please re

  14. Slide 14: Sep 30, 2006 Balance Sheet

    14 Cash & marketable securities $91 Debt $1,442 Accounts receivable $252 DSOs 70 days Inventory $278 Days of Inventory 150 days $ in millions Sep 30, 2006 Balance Sheet $651 $552 $188 67 days $153 111 days Dec 31, 2005 $163 $100 $186 71 days $151 118 days Oct 1, 2005

  15. Slide 15: Near-term priorities

    15 Near-term priorities o Deliver on strong Q4 performance o Meet milestones for integration of Serologicals o Drive growth initiatives o Focus on cash flow improvement

Millipore — Q3 2006 Earnings Presentation on 6ix